Ind-swift Laboratories Ltd. · NSE:INDSWFTLAB
Ind-swift Laboratories — Q3 FY26 Earnings Presentation
27 slides from Ind-swift Laboratories's earnings presentation, Feb 4, 2026
Slide 1: Exchange intimation letter: investor presentation on Q3 results
Ref: ISLL:CH:2026 Date: 4th February, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mu
Slide 2: Ind-Swift Laboratories Limited Investor Presentation
Ind - Swift Laboratories Limited Leading Finished Dosage Formulation Manufacturer INVESTOR PRESENTATION 1
Slide 3: Chairman's message
“Revenue remained stable for Q3 FY26, while a reduction in raw material and employee benefit expenses drove a 6.60% increase in Operating EBITDA and an Operating EBITDA margin expansion of approximately 48 BPS. This improvement in operational efficiency, translated to a 22.60% rise in Net Profit (PA
Slide 4: Ind-Swift Group Strategic Evolution
Ind-Swift Group | Strategic Evolution 1997 1998 2004 2005 2007 2011 2012-23 Inception of Setup of API US 2nd plant USFDA PMD / ANVISA Manufacturing Subsidiary commissioned Approval USFDA Approval Ind-Swift Facility Incorporated in Jammu Approval FDA Laboratories Inspection Ltd. Divested API Unit Gro
Slide 5: Core Business Capabilities
DMFs Filed across 33 Therapeutic APIs across Team Size molecules categories Incorporated in 1995 as part of the Ind-Swift Group. 30+ 2500+ 481+ 18 Built as the Group’s dedicated API & CRAMS entity. Among India’s largest standalone API manufacturers Leadership in macrolides & complex chemistry Regula
Slide 6: Synthimed Labs Transaction Summary and Strategic Rationale
Synthimed Labs Transaction Summary Strategic Rationale Slump Sale : Transaction Value : Debt Elimination: Proceeds used to repay entire external debt API & CRAMS business sold to Synthimed Labs Pvt. Ltd. Balance Sheet Reset: Transition from a leveraged profile to net ₹1,650 Cr debt-free Portfolio co
Slide 7: Post-Transformation Overview and Key Metrics
Post-Transformation Overview Key Metrics • Strategic exit from API & CRAMS through a ₹1,650 Cr slump sale, making ISLL net debt-free. 750+ 520+ 38+ • Ind-Swift Limited merged into Ind-Swift Laboratories Limited Product Approvals Years of (Effective 31 March 2024, NCLT-approved). registrations global
Slide 8: Domestic Unit and Global Business Unit facilities
Domestic Unit Global Business Unit (GBU) Samba, J&K Derabassi, Punjab • Strategic Status: 100% Export Oriented Unit (EOU) - Primary revenue engine. • Scale: Spans ≈81,325 sq. meters. • Focus: Domestic formulations • Capabilities: Dedicated blocks for Oral Solid (Ethical, Generics, P2P, & others.) Do
Slide 9: R&D Infrastructure & Capabilities
Infrastructure & Capabilities • Dedicated Formulation R&D Centre in Panchkula, approved by DST (Govt. of India). • 60+ specialized scientists focused on Finished Dosage development. • Strong analytical capabilities: stability studies (ICH), data profiling & analytical method validation. Core Strengt
Slide 10: International and Domestic Engines
Infrastructure International& Capabilities Engine (Global Business Unit) Domestic Engine (India Operations) Focus: High-Value Exports & Regulated Market Comprehensive Market Coverage via multiple Strategic Verticals • Dossier-driven model for regulated & semi-regulated markets Domestic Division serv
Slide 11: Revenue breakup by geography
53% Europe 5% Canada 5% Approx 3% Middle East Others 16% South East Asia 5% UAE 5% 8% Africa Australia 10
Slide 12: Global CMO Market Overview
80 Global CMO Market Overview (In USD Billions) 73.75 70 2024 2030 60 56.09 51.91 50 40 30.88 30 20 15.73 10.48 9 10 6.65 2.13 3.6 2.03 3.99 0.83 1.33 0 UAE South Africa Australia Middle East Canada Europe USA Source Source Source Source Source Source Source • Growing demand for quality • Stringent
Slide 13: Product registrations by region
88 CIS + 10 Russia 10 Canada 73 Europe 34 GCC 48 UAE 146 South East Asia 166 Africa + FWA 166 Africa + FWA 146 South East Asia 81 Latin America 81 Latin America 88 CIS + 10 Russia 48 UAE 73 Europe 39 Australia 39 Australia 34 GCC 6 New 10 Canada Zealand 6 New Zealand 12
Slide 14: Regulated and emerging market approvals
Canada Russia United Kingdom Geneva UAE Taiwan Saudi Australia Regulated Markets Emerging Markets Future Regulatory Targets (Growth Triggers) UK-MHRA (United Kingdom). WHO-GMP (Geneva). 2025: Scheduled inspections for Saudi FDA (SFDA) TGA (Australia). MoH UAE. and Taiwan FDA. Health Canada (Canada).
Slide 15: Products: top product revenue and market size
Market Size Market Size Top Product Revenue Wise Breakup Products FY24 FY25 2024/25 2030-35 Source FY25 (INR Lakhs) (In USD Billions) (In USD Billions) Fexofenadine 7666.17 7967.32 1.5 2.1 Link 2.00% 3.00% 3.00% Atorvastatin 3189.88 4795.71 11.86 19.09 Link 6.00% 22.00% Metformin 2463.59 2571.26 4,0
Slide 16: Products: partner launches and projected revenue
Projected Products Partner Market Commercialization Market Size Market Size Source Revenue Year 2024/5 (In USD Mn) 2030 (In USD Mn) (In USD Mn) Ibuprofen Sachet Viatris Europe 12.00 FY27 112.7 164.1 Link Clarithromycin Dry Viatris Europe 6.00 FY27 2152.2 3501.43 Link Suspension Manx UK Macrogol Sach
Slide 17: Growth drivers
Global Demand Surge Domestic Consumption Boom • Global pharmaceutical market expected to reach • Indian pharma market projected to reach from USD 55 USD 2,350 Billion by 2030. Source Billion USD 130 Billion by 2030, CAGR 12.25%. Source • Strong generic drug demand across regulated + • Chronic diseas
Slide 18: Financial Trajectory and Strategic Growth Triggers
• Viatris Commercialization (FY27) • Commercial supplies begin in 2026, • Topline CAGR 20-25%, scaling from ₹200-220 Cr incremental revenue ₹550 Cr to ₹1,200+ Cr by FY29. expected in FY27. • CDMO to triple over 4 years (₹180 Cr → ₹550-600 Cr) driven by Greenfield Expansion: • 400+ dossier filings by
Slide 19: Leadership team
Mr. N.R. Munjal Mr. Himanshu Jain Chairman and Whole Time Director Managing Director (Domestic Operations) • 40+ years of experience expanding the Group’s • 22+ years of experience specializing in project footprint across 85+ countries with offices in planning, financial strategy, and operational US
Slide 20: Senior management team
Mr. Varun Chabra Mr. Ravi Bhardwaj President – International Mr. Pardeep Verma Mr. Gagan Agarwal Corporate Affairs Chief Financial Officer Corporate Quality Head Marketing • 35+ Years of Experience across • 25+ years exp, expanded Quality, formulation R&D & • 29+ years exp, Member of ICSI • 20+ year
Slide 21: Quarterly revenue, EBITDA and PAT
Total Revenue (INR Cr.) Operating EBITDA (INR Cr) & Operating PAT (INR Cr) & PAT Margins (%) EBITDA Margins (%) 177.06 12. 00 10.74 10. 00 168.30 9.11 10. 00 9.0 0 8.44 8.55 8.76 162.58 8.0 0 8.12 8.0 0 7.0 0 6.07% 6.0 0 5.95% 6.0 0 5.20% 5.49% 5.46% 5.0 0 4.99% 4.0 0 4.0 0 3.0 0 2.0 0 2.0 0 1.0 0 0
Slide 22: Nine-month revenue, EBITDA and PAT
Total Revenue (INR Cr.) Operating EBITDA (INR Cr) & Operating PAT (INR Cr) & PAT Margins (%) EBITDA Margins (%) 507.93 38.00 40. 00 30. 00 481.76 26.09 35. 00 25. 00 27.62 30. 00 7.89% 20. 00 25. 00 5.63% 20. 00 15. 00 15. 00 5.44% 8.29 10. 00 10. 00 5.0 0 2.01% 5.0 0 0.0 0 0.0 0 9M FY25 9M FY26 9M
Slide 23: Quarterly profit and loss statement
Particulars (INR Cr) Q1 FY26 Q2 FY26 Q3 FY26 Q-o-Q Change (%) Revenue 147.99 150.44 149.48 Operating other income 5.59 6.00 3.69 Non operating other income 8.99 11.86 23.89 Total Revenue 162.58 168.30 177.06 5.21 Raw material expense 71.26 77.24 70.13 Employee benefit expense 32.00 35.73 31.39 Other
Slide 24: Nine-month profit and loss statement
Particulars (INR Cr) 9M FY25 9M FY26 Y-o-Y Change (%) Revenue 404.90 447.91 Operating other income 7.76 15.27 Non operating other income 69.11 44.74 Total Revenue 481.76 507.93 5.43 Raw material expense 215.09 218.63 Employee benefit expense 84.55 99.12 Other expenses 104.74 119.50 Provision for Dou
Slide 25: Balance sheet
Equities & Liabilities (INR Cr) FY25 H1 FY26 Assets (INR Cr) FY25 H1 FY26 Shareholder's Fund Non Current Assets Share Capital 68.74 81.61 PP&E 272.97 285.07 Reserves & Surplus 1095.33 1217.04 Total Equity 1164.08 1298.66 Deferred tax assets 44.63 44.63 Other Non - Current Assets 310.72 426.41 Non Cu
Slide 26: BSE Share Performance and shareholding pattern
As on 01-02-2026 Share Performance From 1st Feb 2025 To 1st Feb 2026 BSE: Share Price ₹ 111.30 Market Capitalization ₹ Crs 908.33 VOLUME close 140 No. of Share Outstanding 81,611,558 250 00000 Face Value ₹ 10.00 120 200 00000 52 Week High ₹ 124.45 100 52 Week Low ₹ 67.15 150 00000 80 As on 31-12-202
Slide 27: Thank You
ThankYou ```` Investor & Public Relations Consultant Ind Swift Laboratories Ltd. SCO 850, NAC, Shivalik Enclave, 103-8, Lodha Eternis, MIDC, Manimajra, Chandigarh, Andheri East, Mumbai 400093 1600101, India Maharashtra, India. Phone: +91 9814131627 Phone: +91 85911 45959 Email: investor@indswiftlabs
Ind-Swift Laboratories — Q3 FY26 Earnings Presentation on 6ix